|
第一部份: Andersen TI, Eiken HG, Couch F, Kaada G, Skrede M, Johnsen H, Aloysius TA, Tveit KM, Tranebjerg L, Dorum A, Moller P, Weber BL, Borresen-Dale A-L: Constant denaturant gel electrophoresis(CDGE)in BRCA1 mutation screening. Hum mutat 11: 166-174, 1998 Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Ins 91: 339-346, 1999 Catteau A, Harris WH, Xu CF, Solomon E: Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18: 1957-1965, 1999 Couch FJ, Weber BL, and the Breast Cancer Information Core (BIC): Mutations and polymorphisms in the families early onset breast cancer (BRCA1) gene. Hum Mutat 8: 8-18, 1996 Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. The N Eng. J. Med 336: 1409-1415, 1997 Deng C-X, Brodie SG: Roles of BRCA1 and its interacting proteins. BioEssays 22: 728-737, 2000 Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS: Loss of Heterozygosity in normal tissue adjacent to breast carcinomas. Science 274: 2057-2059, 1996 Dobrovic A, Simpfendorfer D: Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57: 3347-3350, 1997 Friedman LS, Ostermeyer A, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8: 399-404, 1994 Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzańska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubiński J: Founder mutation in the BRCA1 gene in Polish families with breast/ovarian cancer. Am J Hum Genet 66: 1963-1968, 2000 Hakansson S, Johansson O, Johansson U, Sellberg G, Loman N, Gerdes A-M, Holmberg E, Dahl N, Pandis N, Kristoffersson U: Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J Hum Genet 60: 1068-1078, 1997 Ho GH, Phang BH, Ng ISL, Law HY, Soo KC, Ng EH: Novel germline BRCA1 mutations detected in women in Singapore who developed breast carcinoma before the age of 36 years. Cancer 89: 811-816, 2000 Hogervorst FBL, Cornelius RS, Bout M, Van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Devilee P, Ommen G-JB: Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genet 10: 208-212, 1995 Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA: Growth retardation and tumour inhibition by BRCA1. Nat Genet 12: 298-302, 1996 Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, Nagao M: Germline mutation of BRCA1 in Japanese breast cancer. Cancer Res 55: 3521-3524, 1995 Iwase H, Iwata H, Toyama T, Hara Y, Omoto Y, Ando Y, Nakamura T, Kobayashi S: The Clinical Value of Microsatellite Instability and a Loss in Heterozygosity in Sporadic Breast Cancers. Breast Cancer 25: 234-238, 1997 Jose’ Rafael B, Jose’ H-Y: Adaptation of conformation-sensitive gel electrophoresis to an ALFexpressTM DNA sequencer to screen BRCA1 mutations. BioTechniques 28: 1019-1025, 2000 Kainu T, Desper R, Juo S-HH, Schaffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi O-P, Trikkonen M, Syrjakosk K, Kuukasjarvi T, Koivisto P, Karhu R, Holli K, Arason A, Johannesdottir G, Bergthorsson JT, Johannsdottir H, Egilsson V, Barkardottir RB, Johannsson O, Haraldsson K, Sandberg T, Holmberg E, Gronberg H, Olsson H, Borg A, Vehmanen P, Eerola H, Heikkila P, Pyrhonen S, Nevanlinna H: Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci 97: 9603-9608, 2000 Katagiri T, Emi M, Ito I, Kobayashi K, Yoshimoto M, Iwase T, Kasumi F, Miki Y, Skolnick MH, Nakamura Y: Mutations in the BRCA1 genes in Japanese breast cancer patients. Hum Mutant 7: 334-339, 1996 Knudson AG Jr.: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971 Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336: 1416-1421, 1997 Lasko D, Cavenee WK, Nordenskjold M: Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25: 281-314, 1991 Liede A, Cohen B, Black DM, Davidson RH, Renwick A, Hoodfar E, Olopade OI, Micek M, Anderson V, De Mey R, Fordyce A, Warner E, Dann JL, King MC, Weber B, Narod SA, Steel CM: Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer 82: 705-711, 2000 Li SS-L, Tseng H-M, Yang T-P, Liu C-H, Teng S-J, Huang H-W, Chen L-M, Kao H-W, Chen JH, Tseng J-N, Chen A, Hou M-F, Huang T-J, Chang H-T, Mok K-T, Tasi J-H: Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. Hum Genet 104: 201-204, 1999 Malone KE, Daling JR, Thompson JD, O’Brien CA, Francisco LV, Ostrander EA: BRCA1 mutations and breast cancer in the general population. JAMA 279: 922-929, 1998 Mancini DM, Rodenhiser DI, Ainsworth PJ, O’Malley FP, Singh SM, Xing W, Archer TK: CpG methylation within the 5’ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16: 1161-1169, 1998 Markoff A, Sormbrine H, Bogdanova N, Preisler-Adams S, Ganev V, Dworniczak B, Horst J: Comparison of conformation -sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols. Eur J Hum Genet 6: 145-150, 1998 Matsushima M, Kobayashi K, Emi M, Saito H, Saito J Suzumori K, Nakamura Y: Mutations analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet 4: 1953-1956, 1995 Miki Y, Swensen J, Sattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Brustow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994 Offit K, Gilewski T, McGuire P, Schluger A, Hampel H, Brown K, et al.: Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet 347: 1643-1645, 1996 Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutation in patients with early-onset breast cancer. J Natl Cancer Inst 91: 943-949, 1999 Plummer SJ, Anton-Culver H, Webster L, Noble B, Liao S, Kennedy A, Belinson J, Casey G: Detection of BRCA1 mutation by the protein truncation test. Hum Molec Genet 4: 1989-1991, 1995 Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, Ponder BAJ, Olah E: Analysis of BRCA1 and BRCA2 mutations in hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 60: 1242-1246, 1997 Rice JC, Futscher BW: Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res 28: 3233-3239, 2000 Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI: BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84: 258-262, 1999 Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM: Mutations in BRCA1 and BRCA2 in Breast Cancer Families: Are There More Breast Cancer-Susceptibility Genes?Am J Hum Genet 60: 486-495, 1997 Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, et al.: A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273: 535-541, 1995 Shen C-Y, Yu J-C, Lo Y-L, Kuo C-H, Yue C-H, Jou Y-S, Huang C-S, Lung J-C, Wu C-W: Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res 60: 3884-3892, 2000 Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc J-F, Belanger C, Dion F, Liu Q, Skolnick M, Goldgar D, Shattuck-Eidens D, Labrie F, Narod SA: Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 8: 392-398, 1994 Sztan M, Papai Z, Szendroi M, Looij M, Olah E: Allelic Losses from Chromosome 17 in Human Osteosarcomas. Pathol Oncol Res 3: 115-120, 1997 van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, Toth J, Devilee P, King MC, Olah E: Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86: 737-740, 2000 van Der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E: Founder BRCA1 mutation and two novel germline BRCA2 mutation in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutant 15: 480-1, 2000 Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjakoski K, Pyrhonen S, Kallioniemi O-P: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6: 2309-2315, 1997 Venkitaraman AR: Breast cancer genes and DNA repair. Science 286: 1100-1102, 1999 Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ: Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinoma. Nat Genet 21: 236-240, 1999 Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, Okuyama T, Shimada T, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R: Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5: 1249-61, 1999 第二部分: Aral B, de Saint Basile G, Al-Garawi S, Kamoun P, Ceballos-Picot I (1996) Novel nonsense mutation in the hypoxanthine guanine phosphoribosyltransferase gene and nonrandom X-inactivation causing Lesch-Nyhan syndrome in a female patient. Hum Mutant 7: 52-58 Avner P, Heard E (2001) X-chromosome inactivation: counting, choice and initiation. Nature Rev Genet 2: 59-67 Azofeifa J, Voit T, Hubner C, Cremer M (1995) X chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance of activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes. Hum Genet 96: 167-176 Bailey JA, Carrel L, Chakravarti A, Eichler EE (2000) Molecular evidence for a relationship between LINE-1 elements and X chromosome inactivation: The Lyon repeat hypothesis. PNAS 97: 6634-6639 Brown CJ (1996) Role of the X chromosome in cancer. J Natl Cancer Inst 88: 480-482 Buekers TE, Lallas TA, Buller RE (2000) Xq22.2-3 loss of heterozygosity is associated with germline BRCA1 mutation in ovarian cancer. Gynecol Oncol 76: 418-422 Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS (1999) Associated between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst 91: 339-346 Busque L, Mio R, Mattioli J, Brais E, Blais N, Lalonde Y, Maragh M, Gilliland DG (1996) Nonrandom X-inactivation patterns in normal females: Lyonization ratios vary with age. Blood 88: 59-65 Chao W, Huynh KD, Spencer RJ, Davidow LS, Lee JT (2001) CTCF, a candidate trans-acting factor for X-inactivation Choice. Science 6: 1-3 Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung SW, Lee JB, Kerr J, Chenevix-Trench G, Kim S, Barrett JC, Koi M (1997) Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer 20: 234-242 Choi C, Kim MH, Juhng SW (1998) Loss of heterozygosity on chromosome Xp22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas. J Korean Med Sci 13: 311-316 Chuaqui R, Silva M, Emmert-Buck M (2001) Allelic deletion mapping on chromosome 6q and X chromosome inactivation clonality patterns in cervical intraepithelial neoplasia and invasive carcinoma. Gynecol Oncol 80: 364-371 Clarke JT, Greer WJ, Strasberg PM, Pearce RD, Skomorowski MA, Ray PN (1991) Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosome in a karyotypically normal girl. Am J Hum Genet 49: 289-297 Clarke JT, Wilson PJ, Morris CP, Hopwood JJ, Richards RI, Sutherland GR, Ray PN (1992) Characterization of a deletion at Xq27-q28 associated with unbalanced inactivation of the nonmutant X chromosome. Am J Hum Genet 51: 316-322 Dahl N, Hu LJ, Chery M, Fardeau M, Gilgenkrantz S, Nivelon-Chevallier A, Sidaner-Noisette I, Mugneret F, Gouyon JB, Gal A, Kioschis P, d’Urso M, Mandel JL (1995) Myotubular myopathy in a girl with a deletion at Xq27-q28 and unbalanced X inactivation assigns the MTM1 gene to a 600-kb region. Am J Hum Genet 56: 1108-1115 Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS (1996) Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas. Science 274: 2057-2059 Fey MF, Peter HJ, Hinds HL, Zimmermann A, Liechti-Gallati S, Gerber H, Studer H, Tobler A (1992) Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe. J Clin Invest 89: 1438-1444 Fialkow PJ (1973) Primordial cell poll size and lineage relationships of five human cell types. Ann Hum Genet 37: 39-48 Gale RE, Linch DC (1994) Intepretation of X-chromosome inactivation pattern. Blood 84: 2376-2378 Gale RE, Wheadon H, Boulos P, Linch DC (1994) Tissue specificity of X-chromosome inactivation patterns. Blood 83: 2899-2905 Gale RE, Wheadon H, Linch DC (1991) X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. B J Haematol 79: 193-197 Heard E, Clerc P, Avner P (1997) X-chromosome inactivation in mammals. Annu Rev Genet 31: 571-610 Kattar MM, Kupsky WJ, Shimoyama PK, Vo TD, Olson MW, Bargar GR, Sarkar FH (1997) Clonal analysis of gliomas. Hum Pathol 28: 1166-1179 Kristiansen M, Langerod A, Kundsen GP, Weber BL, Borresen-Dale AL, Orstavik KH (2002) High frequency of skewed X inactivation in young breast cancer patients. J Med Genet 39: 30-33 Knudson AG Jr. (1971) Mutation and Cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823 Knudson AG Jr. (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914-10921 Kubota T, Oga S, Ohashi H, Iwamoto Y, Fukushima Y (1999) Borjeson-Forsman-Lehmann syndrome in a woman with skewed X-chromosome inactivation. Am J Med Genet 26: 258-261 Migeon BR (1994) X-chromosome inactivation: molecular mechanisms and genetic consequences. Trends Genet 10: 230-235 Monk M, Harper MI (1979) Sequential XCI coupled with cellular differentiation in early mouse embryos. Nature 281: 311-313 Naumova AK, Plenge RM, Bird LM, Leppert M, Morgan K, Willard HF, Sapienza C (1996) Heritability of X chromosome-inactivation phenotype in a large family. Am J Hum Genet 58: 1111-1119 Nisen PD, Waber PG (1989) Nonrandom X chromosome DNA methylation patterns in hemophiliac females. J Clin Invest 83: 1400-1403 Parolini O, Ressmann G, Hass OA, Pawlowsky J, Gadner H, Knapp W, Holter W (1998) X-linked Wiskott-Aldrich syndrome in a girl. N Engl J Med 338: 291-295 Piao Z, Malkhosyan SR (2002) Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosome Cancers 33: 262-269 Schmidt M, Certoma A, Du Sart D, Kalitsis P, Leversha M, Fowler K, Sheffield L, Jack I, Danks DM (1990) Unusual X chromosome inactivation in a mentally retarded girl with an interstitial deletion Xq27: implications for the fragile X syndrome. Hum Genet 84: 347-352 Shan L, Yang Q, Nakamura M, Nakamura Y, Mori I, Sakurai T, Kakudo K (2000) Active allele loss of the androgen receptor gene contributes to loss of androgen receptor expression in female breast cancers. Biochem Biophys Res Commun 275: 488-492 Tan SS, Williams EA, Tam PPL (1993) X-chromosome inactivation occurs at different times in different tissues of the post-implantation mouse embryo. Nat Genet 3: 170-174 Uehara S, Hashiyada M, Sato K, Sato Y, Fujimori K, Okamura J (2001) Preferential X-chromosome inactivation in women with idiopathic recurrent pregnancy loss. Fertility and Sterility 76: 908-914 Walsh DS, Peacocke M, Harrington A, James WD, Tsou HC (1998) Patterns of X chromosome inactivation in sporadic basal cell carcinomas: evidence for clonality. J Am Acad Dermatol 38: 49-55 Willard HF, Brown CJ, Carrel L, Hendrich B, Miller AP (1993) Epigenetic and chromosome control of gene expression: molecular and genetic analysis of X chromosome inactivation. Cold Spring Harb Symp Quant Biol 58: 315-322
|